A new class-action lawsuit alleges CVS Caremark unlawfully changed its coverage for popular GLP-1 drug Zepbound. | A new ...

The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative ...

As evidence grows supporting the potential health benefits of obesity drugs like Novo Nordisk’s Wegovy and Eli Lilly & Co.’s Zepbound, so too — frustratingly — do the barriers to accessing them.

A class action lawsuit has been filed against CVS Caremark (NYSE:CVS), the pharmacy benefit manager for health insurer Aetna, ...

A class-action lawsuit accuses CVS Caremark of denying medically necessary treatments by stopping coverage of Zepbound, Eli ...

CVS Caremark was sued Wednesday by two health plan participants who say the pharmacy benefit manager wrongly refuses to cover ...

CVS Caremark is facing multiple federal lawsuits by patients challenging its decision to remove weight-loss drug Zepbound ...

GLP-1 medications like Ozempic show promise for multiple health conditions, as experts explore microdosing benefits for blood ...

A class-action lawsuit has been filed against CVS Caremark over its decision to stop covering Zepbound, Eli Lilly’s ...

Dr. Buettner points out that glucagon, which is targeted by the new medication, can raise a person’s heart rate and may ...

While a recent head-to-head trial of the obesity med heavyweights Wegovy and Zepbound favored the latter drug from Eli Lilly on weight loss, Novo Nordisk has now countered that result with ...

These stocks have climbed in the triple digits over the past three years. Gains may be far from over as demand for these ...